Sian Fereday

List of Publications by Year
in descending order

49 papers	10,863 citations	147726 31 h-index	197736 49 g-index
50 all docs	50 docs citations	50 times ranked	15817 citing authors

#	Article	IF	Citations
1	Pan-cancer analysis of whole genomes. Nature, 2020, 578, 82-93.	13.7	1,966
2	ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas. New England Journal of Medicine, 2010, 363, 1532-1543.	13.9	1,460
3	Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome. Clinical Cancer Research, 2008, 14, 5198-5208.	3.2	1,312
4	Wholeâ€"genome characterization of chemoresistant ovarian cancer. Nature, 2015, 521, 489-494.	13.7	1,206
5	BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutationâ€"Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 2012, 30, 2654-2663.	0.8	1,018
6	Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. Journal of Pathology, 2010, 221, 49-56.	2.1	617
7	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. Journal of Clinical Investigation, 2013, 123, 517-25.	3.9	462
8	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncology, The, 2013, 14, 853-862.	5.1	335
9	Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas. Clinical Cancer Research, 2009, 15, 1417-1427.	3.2	266
10	Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with <scp>HER2</scp> targeting in 19% of carcinomas. Journal of Pathology, 2013, 229, 111-120.	2.1	169
11	Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. Journal of Clinical Oncology, 2017, 35, 1274-1280.	0.8	157
12	Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. Clinical Cancer Research, 2015, 21, 652-657.	3.2	138
13	Analysis of cancer risk and BRCA1 and BRCA2mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Research, 2006, 8, R12.	2.2	135
14	Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. Nature Communications, 2019, 10, 1295.	5.8	133
15	The molecular origin and taxonomy of mucinous ovarian carcinoma. Nature Communications, 2019, 10, 3935.	5.8	110
16	Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors. Molecular Cancer Research, 2008, 6, 1678-1690.	1.5	108
17	LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. Cancer Research, 2012, 72, 4060-4073.	0.4	100
18	Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver. Clinical Cancer Research, 2014, 20, 6618-6630.	3.2	96

#	Article	IF	Citations
19	ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. Clinical Cancer Research, 2008, 14, 5594-5601.	3.2	90
20	Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 2020, 31, 1240-1250.	0.6	85
21	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2018, 24, 569-580.	3.2	79
22	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. British Journal of Cancer, 2014, 111, 2297-2307.	2.9	76
23	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261.	1.3	70
24	EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. Cancer Research, 2017, 77, 4268-4278.	0.4	56
25	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecologic Oncology, 2013, 131, 8-14.	0.6	55
26	Reducing Time to Diagnosis Does Not Improve Outcomes for Women With Symptomatic Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 2011, 29, 2253-2258.	0.8	52
27	Therapeutic options for mucinous ovarian carcinoma. Gynecologic Oncology, 2020, 156, 552-560.	0.6	49
28	Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecologic Oncology, 2014, 133, 16-22.	0.6	47
29	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	3.2	43
30	Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. Clinical Cancer Research, 2019, 25, 3962-3973.	3.2	36
31	Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nature Reviews Cancer, 2019, 19, 339-348.	12.8	35
32	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	2.9	35
33	Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecologic Oncology, 2018, 150, 239-246.	0.6	32
34	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. Molecular Cancer Therapeutics, 2015, 14, 1495-1503.	1.9	26
35	The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer. Human Molecular Genetics, 2016, 25, ddw362.	1.4	26
36	Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nature Communications, 2021, 12, 3039.	5.8	24

#	Article	IF	Citations
37	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	1.4	22
38	High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival. PLoS ONE, 2013, 8, e54356.	1.1	22
39	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology, 2021, 34, 194-206.	2.9	21
40	BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. JCO Precision Oncology, 2018, 2, 1-14.	1.5	19
41	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. Gynecologic Oncology, 2016, 142, 458-464.	0.6	17
42	The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Research, 2001, 3, 346-9.	2.2	13
43	Characterisation and validation of Mel38; A multi-tissue microRNA signature of cutaneous melanoma. PLoS ONE, 2019, 14, e0211504.	1.1	6
44	Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1669-1680.	1.1	5
45	Translation of a circulating miRNA signature of melanoma into a solid tissue assay to improve diagnostic accuracy and precision. Biomarkers in Medicine, 2021, 15, 1111-1122.	0.6	4
46	TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members. Journal of Clinical Oncology, 2022, , JCO2102108.	0.8	3
47	Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 680-688.	1.1	2
48	Germline BRCA variants, lifestyle and ovarian cancer survival. Gynecologic Oncology, 2022, , .	0.6	2
49	The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer. , 2021, , 43-53.		0